Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Zymeworks Appoints Dr. To Its Board Of Directors August 2, 2017 Ipsen Names New CEO for Its North America Biz January 11, 2018 Repligen To Report Second Quarter 2017 Financial Results July 26, 2017
